Role of fibroblast growth factor 23 in the development of cardiovascular diseases in patients with end-stage renal failure on programmed hemodialysis
Aim. To determine the nature of changes in fibroblast growth factor 23 (FGF-23) and other bone mineral metabolism parameters detectable in the blood of patients with end-stage chronic renal failure (CRF) and to analyze their links to the development of cardiovascular events in uremic intoxication. S...
Main Authors: | F U Dzgoeva, M Yu Sopoev, T L Bestaeva, O V Khamitsaeva, F A Ktsoeva, R O Sageeva |
---|---|
Format: | Article |
Language: | Russian |
Published: |
"Consilium Medicum" Publishing house
2016-12-01
|
Series: | Терапевтический архив |
Subjects: | |
Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/32079/pdf |
Similar Items
-
Fibroblast growth factor 23 and a novel high-sensitivity troponin I: Early markers and alternative ways of damaging the heart in chronic kidney disease
by: F U Dzgoeva, et al.
Published: (2015-06-01) -
Osteoprotegerin and fibroblast growth factor 23 in the development of cardiovascular events in chronic kidney disease
by: F U Dzgoeva, et al.
Published: (2014-06-01) -
Fibroblast growth factor-23 (FGF-23) / soluble Klotho protein (sKlotho) / sclerostin glycoprotein ratio disturbance is a novel risk factor for cardiovascular complications in ESRD patients receiving treatment with regular hemodialysis or hemodiafiltration
by: L Yu Milovanova, et al.
Published: (2018-06-01) -
Correlation of serum levels of fibroblast growth factor 23 and Klotho protein levels with bone mineral density in maintenance hemodialysis patients
by: Shubei Zheng, et al.
Published: (2018-04-01) -
Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction
by: Clotilde Roy, et al.
Published: (2020-10-01)